FluoGuide Begins US Phase II Enrollment for FG001

FluoGuide has initiated enrollment in its US Phase II trial for FG001, targeting high-grade glioma. This marks the company's first trial under a US Investigational New Drug (IND) application and follows a collaboration agreement with Leica Microsystems for the same indication.